



## Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

May 28, 2021

**Online event to include a live reading by Children’s Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards**

COPENHAGEN, Denmark, May 28, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, today announced [an online event](#) with members of the hypoparathyroidism community to be held on Tuesday, June 1 in support of World Hypopara Awareness Day.

The live, online event seeks to raise awareness of hypoparathyroidism worldwide and share Ariana Feiner’s uplifting message of hope and inspiration to those affected by chronic illness.

**Who:** [Ariana Feiner](#), Children’s Author, Filmmaker and Educator  
Liz Glenister, CEO and Founder, [Parathyroid UK](#)  
Bob Sanders, Chairman of the Board, [HypoPARAthyroidism Association, Inc.](#)

**What:** [A Story of Courage: Living with Hypoparathyroidism](#) will include remarks by members of the community, followed by a live reading and discussion

**When:** June 1, 2021

12:00 p.m. Pacific Time (U.S.)  
3:00 p.m. Eastern Time (U.S.)  
8:00 p.m. British Summer Time (U.K.)  
9:00 p.m. Central European Time (Europe)

**Where:** Visit the event page at [www.astoryofcourage.live](#) for more information and to add to your calendar.

#WorldHypoparaDay  
#Hypoparathyroidism  
#AStoryofCourage

### About Hypoparathyroidism (HP) <sup>1,2,3,4,5,6</sup>

Hypoparathyroidism (HP) is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. HP affects approximately 200,000 patients in the United States, Europe, Japan and South Korea, the majority of whom develop the condition following damage or accidental removal of the parathyroid glands during thyroid surgery. Patients often experience decreased quality of life. In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache. Over the long term, this complex disorder can increase risk of major complications, such as extraskeletal calcium depositions occurring within the brain, lens of the eye, and kidneys, which can lead to impaired renal function.

### About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, in Palo Alto and Redwood City, California, and in Princeton, New Jersey.

Please visit [www.ascendispharma.com](#) (for global information) or [www.ascendispharma.us](#) (for U.S. information).

### Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company, (ii) Ascendis’ product pipeline and expansion into additional therapeutic areas and (iii) Ascendis’

expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis' ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 10, 2021 and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

*Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.*  
© May 2021 Ascendis Pharma A/S.

**Investor contacts:**

Tim Lee  
Ascendis Pharma  
(650) 374-6343  
[tle@ascendispharma.com](mailto:tle@ascendispharma.com)

**Media contact:**

Ami Knoefler  
Ascendis Pharma  
(650) 739-9952  
[ack@ascendispharma.com](mailto:ack@ascendispharma.com)

Patti Bank  
Westwicke Partners  
(415) 513-1284  
[patti.bank@westwicke.com](mailto:patti.bank@westwicke.com)  
[ir@ascendispharma.com](mailto:ir@ascendispharma.com)

- <sup>1</sup> Mannstadt M, et al. *Nature Reviews* 2017, 3: 17055
- <sup>2</sup> Ascendis Pharma HP Patient Experience Research.
- <sup>3</sup> Hadker N, et al. *Endo Pract.* 2014, 20(7);671-679.
- <sup>4</sup> Powers J, et al. *J Bone Miner Res* 2013, 28: 2570-2576.
- <sup>5</sup> Mitchell DM, et al. *J Clin Endocrinol Metab* 2012, 97(12): 4507-4514
- <sup>6</sup> Underbjerg L, et al. *J Bone Miner Res* 2013, 28: 2277-2285



Source: Ascendis Pharma